Frontage Holdings 1521.HK · HKD

Its shares trade on HKEX under the ticker 1521.HK. It has been listed since 30 May 2019.

Frontage Holdings Corp. engages in the provision of research, analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania. The company went IPO on 2019-05-30. Its offered services includes drug metabolism and pharmacokinetics, safety and toxicology services, chemistry, manufacturing and control (CMC), agrochemical services, and associated services supporting clinical studies, which includes early stage clinical services and biometrics services. The firm provides its services primarily through its wholly owned subsidiary in the United States, Frontage Laboratories, Inc. (Frontage Labs), and China, Frontage Laboratories (Shanghai) Co., Ltd.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Li SongExecutive Chairman of the Board, since 2021$1.1m
• Dr. Zhongping LinCo-Chief Executive Officer
• Dr. Zhang WentaoCo-Chief Executive Officer
• Mr. Jun GaoChief Financial Officer, since 2018$9,000
• Mr. Richard FischettiVice President, General Counsel
• Ms. Ying Lung ChangCompany Secretary
• Mr. Wu HaoNon-Executive Director$14,000
• Dr. Zhihe LiNon-Executive Director, since 2018$168,000
• Ms. Zhuan YinNon-Executive Director$14,000
• Mr. Yifan LiIndependent Non-Executive Director$44,000
• Mr. Erh Fei LiuIndependent Non-Executive Director$44,000
• Dr. Jingsong WangIndependent Non-Executive Director$44,000

Overall

75

Environment

68

Social

91

Governance

65

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.